Cathie Wood’s ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
One of Cathie Wood's Ark Invest funds bought over 530,000 shares of Fate Therapeutics on July 7.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday. The fund bought over 530,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE), as the price of this ETF was down over 2% on the day. Note that this fund is up significantly in the past year.
Specifically, ARK Innovation ETF (NYSEARCA: ARKK) bought 535,305 shares of Fate Therapeutics. At Wednesday’s closing price, this would have valued this purchase at roughly $46.2 million. Even though this is a small fraction of the total holdings, every little bit counts. The fund is up 60% in the past year.
Here’s a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | PATH | UiPath | 279,284 |
| ARKG | SGFY | Signify Health | 53,916 |
| ARKG | RXRX | Recursion Pharmaceuticals | 204,752 |
| ARKG | RPTX | Repare Therapeutics | 18,190 |
| ARKG | QSI | Quantum-Si | 359,389 |
| ARKG | MASS | 908 Devices | 47,945 |
| ARKK | FATE | Fate Therapeutics | 535,305 |
| ARKK | COIN | Coinbase Global | 20,165 |
| ARKK | TSLA | Tesla | 110,731 |
| ARKQ | PATH | UiPath | 135,228 |
| ARKW | VUZI | Vuzix | 521,151 |
| ARKW | FTCH | Farfetch | 599,955 |
| ARKX | AVAV | Aerovironment | 23,098 |
| ARKX | PATH | UiPath | 25,645 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=909938][wallst_email_signup]
Contact [email protected] for any questions or corrections.






